Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma
Cancer Biomarkers · 2025-06 · 42 (6)
DOI: 10.1177/18758592251344936 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biomarkers, online erschienen am 09.06.2025. Verfasst von Fumou Sun und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Plasma Cells, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: BLRD VA, NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Background
Multiple myeloma (MM) is virtually always preceded by monoclonal gammopathy of undetermined significance (MGUS). Elevated serum markers are used to classify MGUS patients into clinical risk categories. Previous research has indicated that the absence of a normal plasma cell signature in MGUS is linked to early progression.
Objective
To confirm that the presence of a “polyclonal plasma cell (PolyPC) signature” serves as a robust negative predictor of MGUS progression.
Methods
374 MGUS patients were enrolled, including 334 patients with stable disease and 40 patients who progressed to MM within 10 years. An oligonucleotide microarray analysis was performed on mRNA extracted from CD138-selected bone marrow plasma cells to evaluate gene expression profiles. The PolyPC signature was developed and validated to assess its role in predicting disease progression. Statistical analyses included Cox proportional hazards models to evaluate progression risk and receiver operating characteristic (ROC) curve analysis to determine the sensitivity, specificity, and overall predictive performance of the PolyPC score.
Results
Through this retrospective study, we developed PolyPC signature based on gene expression profiles of normal, uninvolved plasma cells to predict MGUS progression risk. ROC analysis demonstrated that this signature accurately predicted the risk of MGUS progression (C-statistic: 0.792). A PolyPC score ≤ 11.6 identified a subset of 89 patients with a 10-year progression probability of 31.5% (28/89), while the remaining 285 patients had a progression probability of only 4.2% (12/285) ( p < 0.01). Sensitivity and specificity were 70% (28/40) and 81.7% (273/334). The external validation using the SWOG-S0120 dataset reinforces the robustness and clinical applicability of the PolyPC score in predicting MGUS progression to MM.
Conclusions
The strength of the PolyPC signature is a powerful negative predictor of MGUS progression. These findings support incorporating PolyPC into MGUS management to identify patients needing more frequent and intensive monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
- Myeloma Center, Department of Internal Medicine, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
- Coppell High School, Coppell, TX, USA.
- Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
- Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
- Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
ORCID-Profile: Fumou Sun, Yan Cheng, Clyde Bailey, David Mery, Timothy Cody Ashby, Daisy Alapat, Yong Li, Samer Al Hadidi, Carolina Schinke, Maurizio Zangari
Förderung
- BLRD VA
- NCI NIH HHS
- National Cancer Institute
- Paula and Rodger Riney Foundation
- Myeloma Solution Fund
- Leukemia and Lymphoma Society
- Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences
- Veterans Administration
Zitieren
APA
Sun, F., Cheng, Y., Ma, C., Xu, H., Bailey, C., Mery, D., Ashby, T. C., Alapat, D., Li, Y., Young, K. H., Al Hadidi, S., Thanendrarajan, S., Schinke, C., Zangari, M., van Rhee, F., Tricot, G., Shaughnessy, J. D., & Zhan, F. (2025). Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma. Cancer Biomarkers, 42(6). https://doi.org/10.1177/18758592251344936
Vancouver
Sun F, Cheng Y, Ma C, Xu H, Bailey C, Mery D, et al. Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma. Cancer Biomarkers. 2025;42(6). doi:10.1177/18758592251344936
BibTeX
@article{Sun2025,
author = {Sun, Fumou and Cheng, Yan and Ma, Catherine and Xu, Hongwei and Bailey, Clyde and Mery, David and Ashby, Timothy Cody and Alapat, Daisy and Li, Yong and Young, Ken H and Al Hadidi, Samer and Thanendrarajan, Sharmilan and Schinke, Carolina and Zangari, Maurizio and van Rhee, Frits and Tricot, Guido and Shaughnessy, John D and Zhan, Fenghuang},
title = {Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma},
journal = {Cancer Biomarkers},
year = {2025},
volume = {42},
number = {6},
doi = {10.1177/18758592251344936}
}
EUVIMED